Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis

Clicks: 356
ID: 112676
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #4 of 17 articles by views in drugs

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation and joint destruction that causes significant morbidity and mortality. However, the combined use of methotrexate (MTX), a synthetic disease-modifying anti-rheumatic drug (sDMARD) and biological DMARDs (bDMARDs) …
Reference Key
y2014drugsintensive Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tanaka Y;Hirata S;;
Journal drugs
Year 2014
DOI
DOI not found
URL
https://www.pubmed.gov/25389048/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review humans pubmed abstract nih national institutes of health national library of medicine arthritis pmid:25389048 pmc4245498 doi:10.1007/s40265-014-0323-4 yoshiya tanaka shintaro hirata antirheumatic agents / pharmacology* rheumatoid* / drug therapy rheumatoid* / physiopathology immunosuppressive agents / pharmacology medication therapy management / trends methotrexate / pharmacology patient acuity remission induction / methods* withholding treatment / trends*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.